Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements
NIBIB - National Institute of Biomedical Imaging and Bioengineering
About This Grant
PROJECT SUMMARY: Background. Traditional drug development is slow, costly, and inefficient, with over 90% of drugs failing in clinical trials. Personalized medicine also faces challenges in accurately matching patients with optimal treatments. "Phase-0" microdosing, involving the delivery of tiny drug doses directly into target tissues, has the potential to transform both drug development and personalized drug selection by directly evaluating drug effects in patients without systemic toxicity and rapidly identifying the best treatment for each individual. Our team is leading the clinical translation of an implantable microdevice (IMD) that provides Phase-0 microdose readouts of multiple drugs in a single patient. IMDs are placed into diseased tissue (most commonly tumors) and subsequently release drugs into spatially discrete microscopic regions. The devices and surrounding tissue are then removed surgically and drug effects are characterized and compared using a multi-omic spatial analysis pipeline. Preclinical and first-in-human IMD trials have been highly promising with unprecedented drug insights. However, surgical resection required for IMD analysis is not feasible or safe in most deep anatomic locations. This has prevented IMD validation and use in most settings where they are needed, including neoadjuvant and aggressive metastatic cancer. A less invasive and safer approach is needed to enable broad clinical application. More specifically, there is a critical and currently unmet need for a nonsurgical interventional device to deliver drug microdoses and subsequently biopsy drug-containing tissues for Phase-0 measurements. Proposal and impact. In Aim 1, we will develop an interventional drug response assay (IDRA) device that will broadly enable biopsy-based Phase-0 measurements from any percutaneously accessible site similar to routine percutaneous biopsies, with similar outpatient workflow and low risk. In Aim 2, we will validate IDRA safety and feasibility in prostate and ovarian cancer pre-clinical models (Aim 2). This will enable clinical investigational trials in neoadjuvant and advanced metastatic prostate and ovarian cancer, two settings where oncologists have expressed a critical and urgent need. In a parallel Aim 3, we will integrate label-free optical imaging into the IDRA and evaluate feasibility to image real-time drug effects directly in tumors (Aim 3). Aim 3 will lay the groundwork for our long-term goal of dynamic in-vivo optical Phase-0 imaging, which would provide unprecedented capability to directly monitor drug response and resistance over time. In the long term, these aims have the potential to broadly transform drug development and personalized treatment selection in diseases throughout the body.
Grant Summary
Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements is a NIBIB - National Institute of Biomedical Imaging and Bioengineering grant providing up to $750K for university, nonprofit, healthcare org. Applications are due 2030-04-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $750K
2030-04-30
- 1Confirm your organization is eligible for Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements from NIBIB - National Institute of Biomedical Imaging and Bioengineering, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIBIB - National Institute of Biomedical Imaging and Bioengineering before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIBIB - National Institute of Biomedical Imaging and Bioengineering's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements: Frequently Asked Questions
Who is eligible for the Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements?
Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements is offered by NIBIB - National Institute of Biomedical Imaging and Bioengineering and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements provide?
Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements provides up to $750K per award from NIBIB - National Institute of Biomedical Imaging and Bioengineering. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements deadline?
Applications for Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements are due 2030-04-30 (open). Because deadlines can change, verify the date with the funder, NIBIB - National Institute of Biomedical Imaging and Bioengineering, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements?
To apply for Development of a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIBIB - National Institute of Biomedical Imaging and Bioengineering.